Shortcut to Body Shortcut to main menu

Invest Korea

Search

Investment News

  • Home
  • Information Center
  • Newsroom
  • Investment News
S. Korea’s top pharmas fly high on growing proprietary sales
Date
2017.11.02
Views
861
According to Pulse by Maeil Business News Korea


South Korea’s top pharmaceutical companies have printed best-ever numbers on their bottom line on fast-growing sales from lucrative proprietary brands in addition to in-licensed and generic products.

Their shares were mostly down on profit-taking after rallying ahead of the release of their earnings

On Wednesday, Yuhan Corporation announced it earned 66.5 billion won ($59.8 million) on a non-consolidated basis in the first nine months of this year on sales of 1.08 trillion won, becoming the first Korean drug company that has hit a revenue milestone of 1 trillion won for three quarters.

The company’s full-year sales have surpassed 1 trillion won since 2014, with the sales increase driven not only by strong results from in-licensed brands such as hepatitis treatment Viread and diabetes treatment Trajenta but by its own novel drug Rosuvamibe. Sales of the hyperlipidemia drug reached 15.3 billion won in the first three quarters this year, up a stunning 253.2 percent from a year earlier.

At 12:45 p.m. Thursday, shares of Yuhan were flat at 207,000 won

Green Cross achieved 356.1 billion won in sales on a consolidated basis for the July-September period alone, the best quarterly performance in its history. Sales for the first three quarters grew 9.7 percent on-year to 961.6 billion won, nearing the 1 trillion won level, on strong sales from its key vaccine and blood products. Exports of intravenous immunoglobulin and other human plasma-derived therapeutic proteins grew by double digits. Such exports are poised to grow further now that the company’s biopharmaceutical plant is fully operational in the United States.

Shares of Green Cross slipped 1.5 percent to 204,500 won.

Hanmi Pharm said its first nine-month operating profit surged 89 percent on-year to 80.8 billion won on a consolidated basis. Hanmi, the most aggressive drug company in R&D spending in Korea, generates 71.5 percent of total revenue from home-grown medicines.

Hanmi shares were down 2.5 percent at 486,500 won.



By Kim Hye-soon and Minu Kim

Copyrights Pulse by Maeil Business News Korea. All Rights Reserved.

Source: Pulse by Maeil Business News Korea (Nov. 2, 2017)


Meta information